25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

MaxCyte Inc
Buy, Hold or Sell?

Let's analyze Maxcyte together

I guess you are interested in MaxCyte Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of MaxCyte Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about MaxCyte Inc

I send you an email if I find something interesting about MaxCyte Inc.

1. Quick Overview

1.1. Quick analysis of Maxcyte (30 sec.)










1.2. What can you expect buying and holding a share of Maxcyte? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p166.19
Expected worth in 1 year
p151.38
How sure are you?
17.8%

+ What do you gain per year?

Total Gains per Share
p-14.81
Return On Investment
-5.4%

For what price can you sell your share?

Current Price per Share
p275.00
Expected price per share
p250.00 - p323.35
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Maxcyte (5 min.)




Live pricePrice per Share (EOD)
p275.00
Intrinsic Value Per Share
p-196.42 - p-73.44
Total Value Per Share
p-30.22 - p92.75

2.2. Growth of Maxcyte (5 min.)




Is Maxcyte growing?

Current yearPrevious yearGrowGrow %
How rich?$221.2m$249.3m-$21m-9.2%

How much money is Maxcyte making?

Current yearPrevious yearGrowGrow %
Making money-$8.8m-$6.7m-$2m-23.5%
Net Profit Margin-87.0%-72.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Maxcyte (5 min.)




2.4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#96 / 322

Most Revenue
#184 / 322

Most Profit
#250 / 322

Most Efficient
#228 / 322
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Maxcyte?

Welcome investor! Maxcyte's management wants to use your money to grow the business. In return you get a share of Maxcyte.

First you should know what it really means to hold a share of Maxcyte. And how you can make/lose money.

Speculation

The Price per Share of Maxcyte is p275.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Maxcyte.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Maxcyte, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p166.19. Based on the TTM, the Book Value Change Per Share is p-3.70 per quarter. Based on the YOY, the Book Value Change Per Share is p-3.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Maxcyte.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.090.0%-0.080.0%-0.080.0%-0.060.0%-0.040.0%
Usd Book Value Change Per Share-0.050.0%-0.050.0%-0.040.0%0.100.0%0.050.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.050.0%-0.050.0%-0.040.0%0.100.0%0.050.0%
Usd Price Per Share4.06-4.01-5.55-5.58-3.42-
Price to Earnings Ratio-11.43--13.29--20.93--31.47--25.49-
Price-to-Total Gains Ratio-84.09--148.81--420.48--287.71-7,040,582.21-
Price to Book Ratio1.94-1.86-2.34-6.88-11.23-
Price-to-Total Gains Ratio-84.09--148.81--420.48--287.71-7,040,582.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.47105
Number of shares288
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.050.10
Usd Total Gains Per Share-0.050.10
Gains per Quarter (288 shares)-13.4628.01
Gains per Year (288 shares)-53.85112.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-54-640112102
20-108-1180224214
30-162-1720336326
40-215-2260448438
50-269-2800560550
60-323-3340672662
70-377-3880784774
80-431-4420896886
90-485-49601008998
100-538-550011201110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.045.00.00.0%0.056.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.014.03.015.0%8.024.013.017.8%8.024.024.014.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.045.00.0%0.00.056.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.014.03.015.0%8.024.013.017.8%8.024.024.014.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of MaxCyte Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.829-3.703-3%-3.050-20%7.706-150%3.693-204%
Book Value Per Share--166.193171.473-3%187.253-11%122.633+36%58.342+185%
Current Ratio--14.30912.773+12%16.033-11%10.988+30%6.351+125%
Debt To Asset Ratio--0.1200.126-4%0.114+5%0.210-43%0.496-76%
Debt To Equity Ratio--0.1370.144-5%0.129+6%0.343-60%0.585-77%
Dividend Per Share----0%-0%-0%-0%
Eps---7.042-6.653-6%-6.059-14%-4.482-36%-2.780-61%
Free Cash Flow Per Share---3.852-4.767+24%-6.417+67%-3.894+1%-2.399-38%
Free Cash Flow To Equity Per Share---3.316-4.402+33%-5.801+75%6.442-151%3.127-206%
Gross Profit Margin--1.7061.867-9%2.024-16%1.873-9%1.863-8%
Intrinsic Value_10Y_max---73.442--------
Intrinsic Value_10Y_min---196.417--------
Intrinsic Value_1Y_max---9.285--------
Intrinsic Value_1Y_min---19.964--------
Intrinsic Value_3Y_max---26.431--------
Intrinsic Value_3Y_min---60.096--------
Intrinsic Value_5Y_max---41.807--------
Intrinsic Value_5Y_min---100.042--------
Market Cap29007825000.000-17%33965526000.00033543594000.000+1%46346593125.000-27%46673590425.000-27%28582376900.000+19%
Net Profit Margin---0.899-0.870-3%-0.720-20%-0.619-31%-0.573-36%
Operating Margin---1.148-1.122-2%-0.991-14%-0.716-38%-0.547-52%
Operating Ratio--2.1482.122+1%2.063+4%1.732+24%1.554+38%
Pb Ratio1.655-17%1.9381.857+4%2.339-17%6.877-72%11.232-83%
Pe Ratio-9.763+15%-11.432-13.293+16%-20.928+83%-31.469+175%-25.495+123%
Price Per Share275.000-17%322.000318.000+1%439.375-27%442.475-27%270.967+19%
Price To Free Cash Flow Ratio-17.849+15%-20.900428.335-105%-17.792-15%46.674-145%4.260-591%
Price To Total Gains Ratio-71.817+15%-84.091-148.812+77%-420.482+400%-287.709+242%7040582.206-100%
Quick Ratio--22.95120.520+12%27.452-16%16.656+38%8.749+162%
Return On Assets---0.037-0.034-9%-0.024-35%-0.040+8%-0.076+104%
Return On Equity---0.042-0.039-8%-0.027-35%-0.060+42%-0.104+147%
Total Gains Per Share---3.829-3.703-3%-3.050-20%7.706-150%3.693-204%
Usd Book Value--221270084.977228300248.623-3%249310486.268-11%163273803.747+36%77676444.797+185%
Usd Book Value Change Per Share---0.048-0.047-3%-0.038-20%0.097-150%0.047-204%
Usd Book Value Per Share--2.0982.164-3%2.364-11%1.548+36%0.736+185%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.089-0.084-6%-0.076-14%-0.057-36%-0.035-61%
Usd Free Cash Flow---5128210.556-6347110.602+24%-8543925.799+67%-5185132.893+1%-3194136.101-38%
Usd Free Cash Flow Per Share---0.049-0.060+24%-0.081+67%-0.049+1%-0.030-38%
Usd Free Cash Flow To Equity Per Share---0.042-0.056+33%-0.073+75%0.081-151%0.039-206%
Usd Market Cap366136767.150-17%428712869.172423387243.468+1%584986698.424-27%589114058.344-27%360766761.232+19%
Usd Price Per Share3.471-17%4.0644.014+1%5.546-27%5.585-27%3.420+19%
Usd Profit---9375384.938-8858013.695-6%-6780703.404-28%-5431658.015-42%-3463594.387-63%
Usd Revenue--10429428.21511360491.443-8%10171742.635+3%9031920.835+15%5864221.331+78%
Usd Total Gains Per Share---0.048-0.047-3%-0.038-20%0.097-150%0.047-204%
 EOD+3 -5MRQTTM+14 -20YOY+10 -245Y+17 -1710Y+15 -19

3.3 Fundamental Score

Let's check the fundamental score of MaxCyte Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.763
Price to Book Ratio (EOD)Between0-11.655
Net Profit Margin (MRQ)Greater than0-0.899
Operating Margin (MRQ)Greater than0-1.148
Quick Ratio (MRQ)Greater than122.951
Current Ratio (MRQ)Greater than114.309
Debt to Asset Ratio (MRQ)Less than10.120
Debt to Equity Ratio (MRQ)Less than10.137
Return on Equity (MRQ)Greater than0.15-0.042
Return on Assets (MRQ)Greater than0.05-0.037
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of MaxCyte Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.296
Ma 20Greater thanMa 50282.800
Ma 50Greater thanMa 100291.360
Ma 100Greater thanMa 200311.850
OpenGreater thanClose275.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About MaxCyte Inc

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-11-14 23:48:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Maxcyte earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • A Net Profit Margin of -89.9% means that -0.90 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of MaxCyte Inc:

  • The MRQ is -89.9%. The company is making a huge loss. -2
  • The TTM is -87.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-89.9%TTM-87.0%-2.9%
TTM-87.0%YOY-72.0%-15.1%
TTM-87.0%5Y-61.9%-25.2%
5Y-61.9%10Y-57.3%-4.6%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-89.9%-5.5%-84.4%
TTM-87.0%-16.0%-71.0%
YOY-72.0%-14.9%-57.1%
5Y-61.9%-18.1%-43.8%
10Y-57.3%-23.4%-33.9%
4.3.1.2. Return on Assets

Shows how efficient Maxcyte is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • -3.7% Return on Assets means that Maxcyte generated -0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of MaxCyte Inc:

  • The MRQ is -3.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.7%TTM-3.4%-0.3%
TTM-3.4%YOY-2.4%-1.0%
TTM-3.4%5Y-4.0%+0.6%
5Y-4.0%10Y-7.6%+3.6%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.7%-2.1%-1.6%
TTM-3.4%-3.4%0.0%
YOY-2.4%-4.0%+1.6%
5Y-4.0%-3.0%-1.0%
10Y-7.6%-4.2%-3.4%
4.3.1.3. Return on Equity

Shows how efficient Maxcyte is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • -4.2% Return on Equity means Maxcyte generated -0.04 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of MaxCyte Inc:

  • The MRQ is -4.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.2%TTM-3.9%-0.4%
TTM-3.9%YOY-2.7%-1.1%
TTM-3.9%5Y-6.0%+2.1%
5Y-6.0%10Y-10.4%+4.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.2%-2.1%-2.1%
TTM-3.9%-3.8%-0.1%
YOY-2.7%-4.2%+1.5%
5Y-6.0%-4.4%-1.6%
10Y-10.4%-5.7%-4.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of MaxCyte Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Maxcyte is operating .

  • Measures how much profit Maxcyte makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • An Operating Margin of -114.8% means the company generated -1.15  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of MaxCyte Inc:

  • The MRQ is -114.8%. The company is operating very inefficient. -2
  • The TTM is -112.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-114.8%TTM-112.2%-2.5%
TTM-112.2%YOY-99.1%-13.1%
TTM-112.2%5Y-71.6%-40.6%
5Y-71.6%10Y-54.7%-16.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-114.8%-13.9%-100.9%
TTM-112.2%-17.5%-94.7%
YOY-99.1%-12.3%-86.8%
5Y-71.6%-17.6%-54.0%
10Y-54.7%-19.8%-34.9%
4.3.2.2. Operating Ratio

Measures how efficient Maxcyte is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 2.15 means that the operating costs are 2.15 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of MaxCyte Inc:

  • The MRQ is 2.148. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.122. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.148TTM2.122+0.025
TTM2.122YOY2.063+0.060
TTM2.1225Y1.732+0.391
5Y1.73210Y1.554+0.177
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1481.327+0.821
TTM2.1221.347+0.775
YOY2.0631.329+0.734
5Y1.7321.371+0.361
10Y1.5541.321+0.233
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of MaxCyte Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Maxcyte is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 14.31 means the company has 14.31 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of MaxCyte Inc:

  • The MRQ is 14.309. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.773. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.309TTM12.773+1.536
TTM12.773YOY16.033-3.260
TTM12.7735Y10.988+1.786
5Y10.98810Y6.351+4.637
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ14.3092.573+11.736
TTM12.7732.666+10.107
YOY16.0332.915+13.118
5Y10.9883.393+7.595
10Y6.3513.514+2.837
4.4.3.2. Quick Ratio

Measures if Maxcyte is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • A Quick Ratio of 22.95 means the company can pay off 22.95 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of MaxCyte Inc:

  • The MRQ is 22.951. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 20.520. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ22.951TTM20.520+2.431
TTM20.520YOY27.452-6.932
TTM20.5205Y16.656+3.864
5Y16.65610Y8.749+7.907
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ22.9511.543+21.408
TTM20.5201.688+18.832
YOY27.4521.900+25.552
5Y16.6562.296+14.360
10Y8.7492.552+6.197
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of MaxCyte Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Maxcyte assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Maxcyte to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.12 means that Maxcyte assets are financed with 12.0% credit (debt) and the remaining percentage (100% - 12.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of MaxCyte Inc:

  • The MRQ is 0.120. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.126. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.120TTM0.126-0.005
TTM0.126YOY0.114+0.011
TTM0.1265Y0.210-0.084
5Y0.21010Y0.496-0.286
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1200.403-0.283
TTM0.1260.397-0.271
YOY0.1140.358-0.244
5Y0.2100.437-0.227
10Y0.4960.457+0.039
4.5.4.2. Debt to Equity Ratio

Measures if Maxcyte is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • A Debt to Equity ratio of 13.7% means that company has 0.14 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of MaxCyte Inc:

  • The MRQ is 0.137. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.144. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.137TTM0.144-0.007
TTM0.144YOY0.129+0.015
TTM0.1445Y0.343-0.199
5Y0.34310Y0.585-0.242
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1370.552-0.415
TTM0.1440.581-0.437
YOY0.1290.528-0.399
5Y0.3430.630-0.287
10Y0.5850.697-0.112
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Maxcyte generates.

  • Above 15 is considered overpriced but always compare Maxcyte to the Medical Devices industry mean.
  • A PE ratio of -11.43 means the investor is paying -11.43 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of MaxCyte Inc:

  • The EOD is -9.763. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.432. Based on the earnings, the company is expensive. -2
  • The TTM is -13.293. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.763MRQ-11.432+1.669
MRQ-11.432TTM-13.293+1.861
TTM-13.293YOY-20.928+7.635
TTM-13.2935Y-31.469+18.176
5Y-31.46910Y-25.495-5.974
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-9.763-0.937-8.826
MRQ-11.432-1.257-10.175
TTM-13.293-2.000-11.293
YOY-20.928-2.341-18.587
5Y-31.469-2.001-29.468
10Y-25.495-2.046-23.449
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of MaxCyte Inc:

  • The EOD is -17.849. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -20.900. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 428.335. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.849MRQ-20.900+3.051
MRQ-20.900TTM428.335-449.235
TTM428.335YOY-17.792+446.127
TTM428.3355Y46.674+381.661
5Y46.67410Y4.260+42.414
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-17.849-1.400-16.449
MRQ-20.900-1.683-19.217
TTM428.335-1.997+430.332
YOY-17.792-5.362-12.430
5Y46.674-3.585+50.259
10Y4.260-4.582+8.842
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Maxcyte is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 1.94 means the investor is paying 1.94 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of MaxCyte Inc:

  • The EOD is 1.655. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.938. Based on the equity, the company is underpriced. +1
  • The TTM is 1.857. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.655MRQ1.938-0.283
MRQ1.938TTM1.857+0.080
TTM1.857YOY2.339-0.482
TTM1.8575Y6.877-5.020
5Y6.87710Y11.232-4.356
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD1.6552.139-0.484
MRQ1.9382.141-0.203
TTM1.8572.324-0.467
YOY2.3393.034-0.695
5Y6.8774.079+2.798
10Y11.2324.526+6.706
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets251,496
Total Liabilities30,235
Total Stockholder Equity221,261
 As reported
Total Liabilities 30,235
Total Stockholder Equity+ 221,261
Total Assets = 251,496

Assets

Total Assets251,496
Total Current Assets175,647
Long-term Assets75,849
Total Current Assets
Cash And Cash Equivalents 37,513
Short-term Investments 119,817
Net Receivables 4,581
Inventory 11,159
Other Current Assets 2,577
Total Current Assets  (as reported)175,647
Total Current Assets  (calculated)175,647
+/-0
Long-term Assets
Property Plant Equipment 32,728
Long Term Investments 42,481
Long-term Assets Other 640
Long-term Assets  (as reported)75,849
Long-term Assets  (calculated)75,849
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,275
Long-term Liabilities17,960
Total Stockholder Equity221,261
Total Current Liabilities
Short-term Debt 878
Accounts payable 953
Other Current Liabilities 7,076
Total Current Liabilities  (as reported)12,275
Total Current Liabilities  (calculated)8,907
+/- 3,368
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt17,650
Long-term Liabilities Other 310
Long-term Liabilities  (as reported)17,960
Long-term Liabilities  (calculated)17,960
+/-0
Total Stockholder Equity
Common Stock1,048
Retained Earnings -194,699
Other Stockholders Equity 414,912
Total Stockholder Equity (as reported)221,261
Total Stockholder Equity (calculated)221,261
+/-0
Other
Capital Stock1,048
Cash and Short Term Investments 157,330
Common Stock Shares Outstanding 104,639
Current Deferred Revenue3,368
Liabilities and Stockholders Equity 251,496
Net Debt -18,985
Net Invested Capital 221,261
Net Working Capital 163,372
Property Plant and Equipment Gross 32,728
Short Long Term Debt Total 18,528



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312019-01-312018-12-312018-09-302018-06-302018-03-312018-01-312017-12-312017-09-302017-06-302017-03-312017-01-312016-12-312016-09-302016-06-302016-03-312016-01-312015-12-312015-09-302015-06-302015-03-312015-01-312014-12-312014-09-302014-06-302014-03-312014-01-312013-09-302013-06-302013-03-312013-01-312012-09-302012-06-302012-03-312012-01-31
> Total Assets 
0
0
0
0
0
0
0
0
0
0
0
6,182
6,301
0
5,917
17,060
6,401
6,401
0
16,422
16,422
16,072
16,072
0
36,960
36,960
31,398
31,398
0
26,772
26,772
24,268
24,268
0
24,773
24,773
29,985
29,985
0
53,377
0
51,780
95,008
93,147
277,690
284,120
290,955
289,777
286,412
286,653
281,544
271,204
266,727
268,274
257,930
251,496
251,496257,930268,274266,727271,204281,544286,653286,412289,777290,955284,120277,69093,14795,00851,780053,377029,98529,98524,77324,773024,26824,26826,77226,772031,39831,39836,96036,960016,07216,07216,42216,42206,4016,40117,0605,91706,3016,18200000000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
765
0
5,946
6,028
0
5,652
16,795
6,194
6,194
0
16,195
16,195
15,791
15,791
0
36,619
36,619
30,550
30,550
0
25,656
25,656
22,450
22,450
0
22,111
22,111
24,452
24,452
16,709
46,863
45,253
45,253
88,447
84,626
269,537
270,433
265,795
257,830
252,282
252,266
246,440
236,619
214,339
190,194
178,674
175,647
175,647178,674190,194214,339236,619246,440252,266252,282257,830265,795270,433269,53784,62688,44745,25345,25346,86316,70924,45224,45222,11122,111022,45022,45025,65625,656030,55030,55036,61936,619015,79115,79116,19516,19506,1946,19416,7955,65206,0285,9460765000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
-765
0
3,409
3,409
0
3,014
14,279
2,412
2,412
0
12,181
12,181
11,727
11,727
0
30,163
30,163
25,342
25,342
0
16,022
16,022
11,248
11,248
0
11,469
11,469
15,211
15,211
-16,709
38,172
0
18,755
78,704
37,423
58,974
47,782
239,777
109,168
43,020
11,065
37,833
54,557
49,170
46,506
22,249
37,513
37,51322,24946,50649,17054,55737,83311,06543,020109,168239,77747,78258,97437,42378,70418,755038,172-16,70915,21115,21111,46911,469011,24811,24816,02216,022025,34225,34230,16330,163011,72711,72712,18112,18102,4122,41214,2793,01403,4093,4090-765000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
1,530
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,733
2,733
3,191
3,191
0
3,440
3,440
1,498
1,498
33,417
0
0
16,008
0
35,969
196,915
207,261
6,499
131,719
189,865
216,275
186,819
161,552
141,070
121,782
135,264
119,817
119,817135,264121,782141,070161,552186,819216,275189,865131,7196,499207,261196,91535,969016,0080033,4171,4981,4983,4403,44003,1913,1912,7332,73300000000000000000001,530000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
1,402
1,402
0
1,233
1,233
1,451
1,451
0
2,227
2,227
2,411
2,411
0
3,742
3,742
3,196
3,196
0
3,763
3,763
4,905
4,905
0
2,792
2,792
3,245
3,245
3,747
3,747
5,172
5,172
4,294
5,719
5,958
6,877
10,747
7,909
8,209
13,567
9,291
7,608
8,167
5,778
5,991
4,581
4,5815,9915,7788,1677,6089,29113,5678,2097,90910,7476,8775,9585,7194,2945,1725,1723,7473,7473,2453,2452,7922,79204,9054,9053,7633,76303,1963,1963,7423,74202,4112,4112,2272,22701,4511,4511,2331,23301,4021,40200000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
194
276
0
429
306
1,245
1,245
0
550
550
318
318
0
1,195
1,195
666
666
0
1,100
1,100
864
864
0
916
916
797
797
787
787
1,003
1,003
985
1,346
3,542
3,307
2,190
1,312
3,276
2,779
2,231
1,882
3,400
3,899
3,210
2,577
2,5773,2103,8993,4001,8822,2312,7793,2761,3122,1903,3073,5421,3469851,0031,00378778779779791691608648641,1001,10006666661,1951,195031831855055001,2451,245306429027619400000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
-765
0
236
273
0
265
265
207
207
0
227
227
281
282
0
341
341
848
848
0
1,116
1,116
1,818
1,818
0
2,662
2,662
5,533
5,533
-16,709
6,514
0
6,527
6,561
8,521
8,153
13,687
25,161
31,947
34,130
34,387
35,105
34,585
52,388
78,080
79,256
75,849
75,84979,25678,08052,38834,58535,10534,38734,13031,94725,16113,6878,1538,5216,5616,52706,514-16,7095,5335,5332,6622,66201,8181,8181,1161,11608488483413410282281227227020720726526502732360-765000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
236
236
0
202
202
207
207
0
227
227
282
282
0
341
341
848
848
0
1,116
1,116
1,818
1,818
0
2,371
2,371
5,533
5,533
6,414
6,414
6,493
6,493
6,478
6,817
7,835
13,371
24,106
31,026
32,941
33,578
34,706
33,988
33,340
34,754
33,930
32,728
32,72833,93034,75433,34033,98834,70633,57832,94131,02624,10613,3717,8356,8176,4786,4936,4936,4146,4145,5335,5332,3712,37101,8181,8181,1161,116084884834134102822822272270207207202202023623600000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,429
42,938
45,031
42,481
42,48145,03142,93818,4290000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
292
292
0
0
100
100
34
34
83
1,704
318
317
1,055
921
1,190
809
0
597
0
0
0
0
000059708091,1909211,0553173181,704833434100100002922920000000000000000000000000000000000
> Total Liabilities 
0
0
0
0
0
0
0
0
0
0
0
7,724
7,948
0
8,420
8,420
9,398
9,484
0
9,354
9,354
10,989
10,989
0
12,153
12,153
11,801
11,801
0
11,419
11,419
11,986
11,986
0
8,379
8,694
16,384
16,384
0
16,167
0
18,555
13,722
14,326
13,574
21,223
28,770
32,554
31,980
32,686
33,726
30,221
33,351
36,107
31,571
30,235
30,23531,57136,10733,35130,22133,72632,68631,98032,55428,77021,22313,57414,32613,72218,555016,167016,38416,3848,6948,379011,98611,98611,41911,419011,80111,80112,15312,153010,98910,9899,3549,35409,4849,3988,4208,42007,9487,72400000000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
4,197
4,279
0
3,264
3,264
5,091
5,091
0
4,245
4,245
5,652
5,652
0
6,784
6,784
6,389
7,240
0
5,837
5,837
6,573
6,573
0
8,379
8,379
9,343
9,343
9,166
9,166
11,614
11,614
11,432
12,534
12,577
15,618
15,548
18,107
16,763
15,427
16,639
13,205
16,649
17,855
13,477
12,275
12,27513,47717,85516,64913,20516,63915,42716,76318,10715,54815,61812,57712,53411,43211,61411,6149,1669,1669,3439,3438,3798,37906,5736,5735,8375,83707,2406,3896,7846,78405,6525,6524,2454,24505,0915,0913,2643,26404,2794,19700000000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
1,444
1,552
0
0
22
806
822
0
0
13
0
14
0
5,019
11
851
854
0
5,046
2,733
0
3,191
0
0
3,440
0
509
0
539
0
673
0
617
572
527
480
439
152
157
475
499
699
774
825
878
87882577469949947515715243948052757261706730539050903,440003,19102,7335,0460854851115,0190140130082280622001,5521,44400000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,019
5,019
851
851
0
5,046
5,046
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000005,0465,04608518515,0195,019000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
1,373
1,373
0
1,385
1,385
2,257
2,257
0
1,585
1,585
3,175
3,175
0
3,234
3,234
4,331
4,331
0
3,037
3,037
1,032
4,123
0
4,292
4,292
2,089
2,089
704
704
890
890
418
645
723
1,820
4,366
2,456
2,087
532
3,502
1,603
447
743
1,674
953
9531,6747434471,6033,5025322,0872,4564,3661,8207236454188908907047042,0892,0894,2924,29204,1231,0323,0373,03704,3314,3313,2343,23403,1753,1751,5851,58502,2572,2571,3851,38501,3731,37300000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
1,381
0
0
1,879
0
2,028
0
0
2,660
0
2,478
0
0
3,549
3,539
2,058
2,055
0
2,800
-2,733
5,541
-3,191
0
4,087
-3,121
7,254
3,552
5,072
2,850
4,843
5,209
11,014
4,518
4,956
6,524
3,871
7,902
8,232
8,025
6,913
6,411
9,918
11,269
6,502
7,076
7,0766,50211,2699,9186,4116,9138,0258,2327,9023,8716,5244,9564,51811,0145,2094,8432,8505,0723,5527,254-3,1214,0870-3,1915,541-2,7332,80002,0552,0583,5393,549002,47802,660002,02801,879001,38100000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
3,527
3,669
0
5,156
5,156
4,307
4,392
0
5,109
5,109
5,337
5,337
0
5,370
5,370
5,412
4,561
0
5,582
5,582
5,414
5,414
0
0
315
7,041
7,041
0
7,002
0
6,940
2,290
1,792
997
5,605
13,222
14,446
15,216
17,260
17,086
17,017
16,702
18,252
18,094
17,960
17,96018,09418,25216,70217,01717,08617,26015,21614,44613,2225,6059971,7922,2906,94007,00207,0417,041315005,4145,4145,5825,58204,5615,4125,3705,37005,3375,3375,1095,10904,3924,3075,1565,15603,6693,52700000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
362
362
385
385
0
535
535
357
357
0
315
315
338
338
375
375
647
647
1,094
1,095
497
450
451
393
345
1,322
0
1,308
0
0
0
0
00001,30801,3223453934514504971,0951,09464764737537533833831531503573575355350385385362362000000000000000000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
0
-1,543
0
-1,542
-1,647
0
-2,503
8,640
-2,997
-3,083
0
7,068
7,068
5,083
5,083
0
24,807
24,807
19,597
19,597
0
15,353
15,353
12,282
12,282
0
16,079
16,079
13,602
13,602
13,602
37,210
0
33,225
81,286
78,821
264,116
262,897
262,185
257,223
254,432
253,967
247,819
240,983
233,377
232,167
226,359
221,261
221,261226,359232,167233,377240,983247,819253,967254,432257,223262,185262,897264,11678,82181,28633,225037,21013,60213,60213,60216,07916,079012,28212,28215,35315,353019,59719,59724,80724,80705,0835,0837,0687,0680-3,083-2,9978,640-2,5030-1,647-1,5420-1,543000000000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
19
19
0
19
434
20
20
0
435
435
435
435
0
508
508
509
509
0
513
513
513
513
0
574
574
574
574
766
766
774
774
847
847
1,004
1,012
1,015
1,017
1,019
1,024
1,029
1,031
1,036
1,040
1,044
1,048
1,0481,0441,0401,0361,0311,0291,0241,0191,0171,0151,0121,00484784777477476676657457457457405135135135130509509508508043543543543502020434190191900000000000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-33,851
0
0
-1,133
0
0
-44,611
0
-1,218
0
0
-1,267
0
-1,319
0
0
-1,311
0
-1,335
0
0
-1,483
0
-1,637
0
0
-1,869
0
-2,198
13,602
-2,467
0
-2,976
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000-2,9760-2,46713,602-2,1980-1,86900-1,6370-1,48300-1,3350-1,31100-1,3190-1,26700-1,2180-44,61100-1,13300-33,851000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96,434
0
125,916
0
127,674
0
184,724
372,542
0
0
0
0
0
0
0
0
0
0
0
00000000000372,542184,7240127,6740125,916096,4340000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
1,133
0
0
55,339
0
1,218
0
56,279
57,546
56,373
57,692
0
80,324
81,635
80,729
82,064
0
81,269
82,752
82,279
83,916
0
95,491
97,360
96,434
98,632
0
128,382
0
130,650
182,767
184,724
372,542
376,190
379,542
382,838
386,479
390,819
395,547
399,220
402,862
406,925
410,639
414,912
414,912410,639406,925402,862399,220395,547390,819386,479382,838379,542376,190372,542184,724182,767130,6500128,382098,63296,43497,36095,491083,91682,27982,75281,269082,06480,72981,63580,324057,69256,37357,54656,27901,218055,339001,133000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue41,288
Cost of Revenue-4,742
Gross Profit36,54636,546
 
Operating Income (+$)
Gross Profit36,546
Operating Expense-84,845
Operating Income-48,299-48,299
 
Operating Expense (+$)
Research Development23,817
Selling General Administrative30,068
Selling And Marketing Expenses26,975
Operating Expense84,84580,860
 
Net Interest Income (+$)
Interest Income10,376
Interest Expense-0
Other Finance Cost-0
Net Interest Income10,376
 
Pretax Income (+$)
Operating Income-48,299
Net Interest Income10,376
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,923-58,675
EBIT - interestExpense = -48,299
-33,920
-37,923
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-48,299-37,923
Earnings Before Interest and Taxes (EBITDA)-44,128
 
After tax Income (+$)
Income Before Tax-37,923
Tax Provision-0
Net Income From Continuing Ops-37,923-37,923
Net Income-37,923
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses89,587
Total Other Income/Expenses Net10,376-10,376
 

Technical Analysis of Maxcyte
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Maxcyte. The general trend of Maxcyte is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Maxcyte's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of MaxCyte Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 294.00 < 310.00 < 323.35.

The bearish price targets are: 250.00 > 250.00 > 250.00.

Tweet this
MaxCyte Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of MaxCyte Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

MaxCyte Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of MaxCyte Inc. The current macd is -5.72551867.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Maxcyte price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Maxcyte. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Maxcyte price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
MaxCyte Inc Daily Moving Average Convergence/Divergence (MACD) ChartMaxCyte Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of MaxCyte Inc. The current adx is 10.96.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Maxcyte shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
MaxCyte Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of MaxCyte Inc. The current sar is 303.46.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
MaxCyte Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of MaxCyte Inc. The current rsi is 44.30. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
MaxCyte Inc Daily Relative Strength Index (RSI) ChartMaxCyte Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of MaxCyte Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Maxcyte price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
MaxCyte Inc Daily Stochastic Oscillator ChartMaxCyte Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of MaxCyte Inc. The current cci is -72.85991915.

MaxCyte Inc Daily Commodity Channel Index (CCI) ChartMaxCyte Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of MaxCyte Inc. The current cmo is -9.25732619.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
MaxCyte Inc Daily Chande Momentum Oscillator (CMO) ChartMaxCyte Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of MaxCyte Inc. The current willr is -70.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Maxcyte is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
MaxCyte Inc Daily Williams %R ChartMaxCyte Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of MaxCyte Inc.

MaxCyte Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of MaxCyte Inc. The current atr is 11.77.

MaxCyte Inc Daily Average True Range (ATR) ChartMaxCyte Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of MaxCyte Inc. The current obv is 172,940.

MaxCyte Inc Daily On-Balance Volume (OBV) ChartMaxCyte Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of MaxCyte Inc. The current mfi is 38.45.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
MaxCyte Inc Daily Money Flow Index (MFI) ChartMaxCyte Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for MaxCyte Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-10MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

MaxCyte Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of MaxCyte Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.296
Ma 20Greater thanMa 50282.800
Ma 50Greater thanMa 100291.360
Ma 100Greater thanMa 200311.850
OpenGreater thanClose275.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Maxcyte with someone you think should read this too:
  • Are you bullish or bearish on Maxcyte? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Maxcyte? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about MaxCyte Inc

I send you an email if I find something interesting about MaxCyte Inc.


Comments

How you think about this?

Leave a comment

Stay informed about MaxCyte Inc.

Receive notifications about MaxCyte Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.